Covestor's Ben Dickey is upbeat about Chesapeake's outlook. Strategies Ben Dickey: Chesapeake better off without McClendon
Aveo's Tivozanib kidney cancer drug will get the nod from regulators. Strategies Why Aveo’s Tivozanib should win FDA approval
Facebook's mobile strategy is starting to deliver. Strategies Five takeaways from Facebook’s Q1 earnings results
The buyback was the only positive I could see in the report. Strategies Eric Steiman: Why I’m staying short Apple
Multiple compression and a movement from growth to value hands. Strategies Charles Sizemore on CNBC: Apple looks like Microsoft 10 years …
The stock market may pause, but low interest rates will bolster equities. Strategies Easy money should support global equities in 2013
The stock market has plenty of supports heading into the second half. Strategies Sell in May? Maybe not this year
